EMA Fluoxetine 20-80 Yes 6 T6 152 65.8 38.0± 9.9 No 39 18 Yes Venlafaxine Venlafaxine 75-375 155 63.9 40.0± 9.5 51 27 trial 1998 (Protocol N.. Placebo 152 59.9 39.0± 10.6 15 16 0600A1-372 US) EMA Venlafaxine 74.8 Yes 8 T8 83 69.8 44.9±12.9 No 2 6 Yes Venlafaxine Venlafaxine 148.2 78 64.1 44.3±10.6 3 7 study 1995 (Protocol N. Paroxetine 20 80 55 48.2±12.5 3 11 Placebo 82 68.2 44.7±11.6 2 2 EMA Venlafaxine 176.6 Yes 8 T8 91 63.7 40 No 33 26 Yes Venlafaxine Placebo 100 59 42 15 11 trial 1996 (Protocol N. 0600B-209-US) (Fabre et al. Fluvoxamine 50-117 No 6 T6 46 76.1 - No 11 19 Yes 1996)() Placebo 44 68.2 - 2 2 (Fabre et al. Paroxetine 28.7 Yes 6 T6 38 55.3 35.6 No - 10 No 1992)() Placebo 36 63.8 35.9 - 6 (Fava et al. Fluoxetine 20-80 Yes 12 T12 54 - 41.3± 12.6 No 11 - Yes 1998)() Paroxetine 20-50 55 - 41.3± 12.6 16 - Placebo 19 - 41.3± 12.6 2 - (Fava et al. Mirtazapine 24.3-27.5 No 8 T8 50 60 43.8± 10.0 No 3 25 Yes 2001)() (Fava et al. Fluoxetine 20 No 12 T12 47 53 36.7 ± 9.6 No 5 6 Yes 2005)() Placebo 43 65 37.8± 12.0 6 3
EMA Venlafaxine 1998 (Protocol N.. 0600A1-372 US) Fluoxetine Venlafaxine Placebo 20-80 75-375 Yes 6 T6 152 155 152 65.8 63.9 59.9 38.0± 9.9 40.0± 9.5 39.0± 10.6 No 39 51 15 18 27 16 Yes EMA Venlafaxine study 1995 (Protocol N. Venlafaxine Venlafaxine Paroxetine Placebo 74.8 148.2 20 Yes 8 T8 83 78 80 82 69.8 64.1 55 68.2 44.9±12.9 44.3±10.6 48.2±12.5 44.7±11.6 No 2 3 3 2 6 7 11 2 Yes EMA Venlafaxine 1996 (Protocol N. 0600B-209-US) Venlafaxine Placebo 176.6 Yes 8 T8 91 100 63.7 59 40 42 No 33 15 26 11 Yes (Fabre et al. 1996)() Fluvoxamine Placebo 50-117 No 6 T6 46 44 76.1 68.2 - - No 11 2 19 2 Yes (Fabre et al. 1992)() Paroxetine Placebo 28.7 Yes 6 T6 38 36 55.3 63.8 35.6 35.9 No - - 10 6 No (Fava et al. 1998)() Fluoxetine Paroxetine Placebo 20-80 20-50 Yes 12 T12 54 55 19 - - - 41.3± 12.6 41.3± 12.6 41.3± 12.6 No 11 16 2 - - - Yes (Fava et al. 2001)() Mirtazapine 24.3-27.5 No 8 T8 50 60 43.8± 10.0 No 3 25 Yes (Fava et al. 2005)() Fluoxetine Placebo 20 No 12 T12 47 43 53 65 36.7 ± 9.6 37.8± 12.0 No 5 6 6 3 Yes trial trial
JCP_00_00_2015_03_31_SERRETTI_JCP14173_SDC1.docx